CN105708934A - Composition capable of stabilizing blood sugar and reducing blood sugar and preparation process thereof - Google Patents
Composition capable of stabilizing blood sugar and reducing blood sugar and preparation process thereof Download PDFInfo
- Publication number
- CN105708934A CN105708934A CN201610267830.XA CN201610267830A CN105708934A CN 105708934 A CN105708934 A CN 105708934A CN 201610267830 A CN201610267830 A CN 201610267830A CN 105708934 A CN105708934 A CN 105708934A
- Authority
- CN
- China
- Prior art keywords
- extract
- blood sugar
- granule
- diabetes
- xylitol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008280 blood Substances 0.000 title claims abstract description 85
- 210000004369 blood Anatomy 0.000 title claims abstract description 84
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 230000000087 stabilizing effect Effects 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims description 15
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 23
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000000811 xylitol Substances 0.000 claims abstract description 23
- 235000010447 xylitol Nutrition 0.000 claims abstract description 23
- 229960002675 xylitol Drugs 0.000 claims abstract description 23
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 23
- 239000000284 extract Substances 0.000 claims description 83
- 239000008187 granular material Substances 0.000 claims description 55
- 239000000843 powder Substances 0.000 claims description 29
- 241000628997 Flos Species 0.000 claims description 26
- 241000233779 Cyclocarya paliurus Species 0.000 claims description 23
- 235000013325 dietary fiber Nutrition 0.000 claims description 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 22
- 239000004386 Erythritol Substances 0.000 claims description 21
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 21
- 229940009714 erythritol Drugs 0.000 claims description 21
- 235000019414 erythritol Nutrition 0.000 claims description 21
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 21
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 21
- 235000010469 Glycine max Nutrition 0.000 claims description 20
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 18
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 18
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 18
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 18
- 238000004806 packaging method and process Methods 0.000 claims description 15
- 239000002671 adjuvant Substances 0.000 claims description 12
- 244000068988 Glycine max Species 0.000 claims description 9
- 238000005516 engineering process Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000004615 ingredient Substances 0.000 claims description 6
- 238000005253 cladding Methods 0.000 claims description 5
- 239000006185 dispersion Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 239000000469 ethanolic extract Substances 0.000 claims description 5
- 238000005469 granulation Methods 0.000 claims description 5
- 230000003179 granulation Effects 0.000 claims description 5
- 244000025254 Cannabis sativa Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 32
- 239000003814 drug Substances 0.000 abstract description 24
- 230000036039 immunity Effects 0.000 abstract description 11
- 235000013305 food Nutrition 0.000 abstract description 10
- 210000004185 liver Anatomy 0.000 abstract description 9
- 230000006870 function Effects 0.000 abstract description 6
- 230000004060 metabolic process Effects 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 5
- 230000002708 enhancing effect Effects 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 235000015097 nutrients Nutrition 0.000 abstract description 2
- 208000035240 Disease Resistance Diseases 0.000 abstract 1
- 206010067482 No adverse event Diseases 0.000 abstract 1
- 229940126673 western medicines Drugs 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 description 72
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 38
- 239000008103 glucose Substances 0.000 description 36
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 33
- 241000283973 Oryctolagus cuniculus Species 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 201000010099 disease Diseases 0.000 description 19
- 102000004877 Insulin Human genes 0.000 description 17
- 108090001061 Insulin Proteins 0.000 description 17
- 230000007812 deficiency Effects 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- 229940125396 insulin Drugs 0.000 description 16
- 230000037396 body weight Effects 0.000 description 12
- 238000003304 gavage Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 210000000952 spleen Anatomy 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 9
- 239000006187 pill Substances 0.000 description 9
- 230000035922 thirst Effects 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 239000000835 fiber Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 150000001720 carbohydrates Chemical class 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 230000000291 postprandial effect Effects 0.000 description 7
- 238000010791 quenching Methods 0.000 description 7
- 210000001124 body fluid Anatomy 0.000 description 6
- 239000010839 body fluid Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 210000001835 viscera Anatomy 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 238000011443 conventional therapy Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 230000008506 pathogenesis Effects 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 230000000171 quenching effect Effects 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- FAMPSKZZVDUYOS-UHFFFAOYSA-N 2,6,6,9-tetramethylcycloundeca-1,4,8-triene Chemical compound CC1=CCC(C)(C)C=CCC(C)=CCC1 FAMPSKZZVDUYOS-UHFFFAOYSA-N 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 229920002527 Glycogen Polymers 0.000 description 4
- 240000007711 Peperomia pellucida Species 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 4
- 235000013405 beer Nutrition 0.000 description 4
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000023852 carbohydrate metabolic process Effects 0.000 description 4
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 229940096919 glycogen Drugs 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000003914 insulin secretion Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 150000005846 sugar alcohols Chemical class 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 239000002023 wood Substances 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 240000005373 Panax quinquefolius Species 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 230000008451 emotion Effects 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- LSDULPZJLTZEFD-UHFFFAOYSA-N lupulone Chemical compound CC(C)CC(=O)C1=C(O)C(CC=C(C)C)=C(O)C(CC=C(C)C)(CC=C(C)C)C1=O LSDULPZJLTZEFD-UHFFFAOYSA-N 0.000 description 3
- 229940126701 oral medication Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000003014 reinforcing effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229940109850 royal jelly Drugs 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- RMFGNMMNUZWCRZ-UHFFFAOYSA-N Humulone Natural products CC(C)CC(=O)C1=C(O)C(O)(CC=C(C)C)C(O)=C(CC=C(C)C)C1=O RMFGNMMNUZWCRZ-UHFFFAOYSA-N 0.000 description 2
- 206010020710 Hyperphagia Diseases 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 101710190529 Insulin-like peptide Proteins 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- CHNUNORXWHYHNE-UHFFFAOYSA-N Oxadiazon Chemical compound C1=C(Cl)C(OC(C)C)=CC(N2C(OC(=N2)C(C)(C)C)=O)=C1Cl CHNUNORXWHYHNE-UHFFFAOYSA-N 0.000 description 2
- 239000005588 Oxadiazon Substances 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000001280 Prediabetic State Diseases 0.000 description 2
- 108010073771 Soybean Proteins Proteins 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 235000013877 carbamide Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 235000005686 eating Nutrition 0.000 description 2
- 230000007937 eating Effects 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- BXWQUXUDAGDUOS-UHFFFAOYSA-N gamma-humulene Natural products CC1=CCCC(C)(C)C=CC(=C)CCC1 BXWQUXUDAGDUOS-UHFFFAOYSA-N 0.000 description 2
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 2
- 229960001381 glipizide Drugs 0.000 description 2
- 230000009229 glucose formation Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical group O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- QBNFBHXQESNSNP-UHFFFAOYSA-N humulene Natural products CC1=CC=CC(C)(C)CC=C(/C)CCC1 QBNFBHXQESNSNP-UHFFFAOYSA-N 0.000 description 2
- VMSLCPKYRPDHLN-NRFANRHFSA-N humulone Chemical compound CC(C)CC(=O)C1=C(O)C(CC=C(C)C)=C(O)[C@@](O)(CC=C(C)C)C1=O VMSLCPKYRPDHLN-NRFANRHFSA-N 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 208000022530 polyphagia Diseases 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 235000019710 soybean protein Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- QHBZHVUGQROELI-SOFGYWHQSA-N (E)-10-hydroxydec-2-enoic acid Chemical compound OCCCCCCC\C=C\C(O)=O QHBZHVUGQROELI-SOFGYWHQSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- QXPOWGXRDUFAQW-LJQANCHMSA-N Adlupulone Natural products O=C([C@@H](CC)C)C=1C(=O)C(C/C=C(\C)/C)(C/C=C(\C)/C)C(O)=C(C/C=C(\C)/C)C=1O QXPOWGXRDUFAQW-LJQANCHMSA-N 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- DRSITEVYZGOOQG-UHFFFAOYSA-N Cohumulone Chemical compound CC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)C(O)(CC=C(C)C)C1=O DRSITEVYZGOOQG-UHFFFAOYSA-N 0.000 description 1
- DRSITEVYZGOOQG-HXUWFJFHSA-N Cohumulone Natural products CC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)[C@](O)(CC=C(C)C)C1=O DRSITEVYZGOOQG-HXUWFJFHSA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 102000004860 Dipeptidases Human genes 0.000 description 1
- 108090001081 Dipeptidases Proteins 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019759 Hepatitis chronic persistent Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- 208000004356 Hysteria Diseases 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- FURUXTVZLHCCNA-UHFFFAOYSA-N Liquiritigenin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-UHFFFAOYSA-N 0.000 description 1
- OLHLJBVALXTBSQ-UHFFFAOYSA-N Lupulone Natural products CC(C)CC(=O)C1C(=O)C(CC=C(C)C)C(=O)C(CC=C(C)C)(CC=C(C)C)C1=O OLHLJBVALXTBSQ-UHFFFAOYSA-N 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- QHBZHVUGQROELI-UHFFFAOYSA-N Royal Jelly acid Natural products OCCCCCCCC=CC(O)=O QHBZHVUGQROELI-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- QXPOWGXRDUFAQW-UHFFFAOYSA-N adlupulone Chemical compound CCC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)C(CC=C(C)C)(CC=C(C)C)C1=O QXPOWGXRDUFAQW-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001194 anti-hemostatic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- WPVSVIXDXMNGGN-UHFFFAOYSA-N beta-bitter acid Natural products CC(C)CC(=O)C1=C(O)C(CC=C(C)C)(CC=C(C)C)C(=O)C(CC=C(C)C)=C1O WPVSVIXDXMNGGN-UHFFFAOYSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000020880 diabetic diet Nutrition 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000001610 euglycemic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 108010046301 glucose peroxidase Proteins 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000000087 hemolymph Anatomy 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 229950004152 insulin human Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229940029329 intrinsic factor Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 230000003212 lipotrophic effect Effects 0.000 description 1
- FURUXTVZLHCCNA-AWEZNQCLSA-N liquiritigenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-AWEZNQCLSA-N 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 229940103453 novolin Drugs 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- GOLXNESZZPUPJE-UHFFFAOYSA-N spiromesifen Chemical compound CC1=CC(C)=CC(C)=C1C(C(O1)=O)=C(OC(=O)CC(C)(C)C)C11CCCC1 GOLXNESZZPUPJE-UHFFFAOYSA-N 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 229930193551 sterin Natural products 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a composition capable of stabilizing blood sugar and reducing blood sugar, which comprises the following components in parts by weight: the main materials are 8; the auxiliary materials are xylitol 3. The formula mainly clears heat and nourishes yin, and regulates liver vigor to reduce blood sugar fundamentally, and stabilizes the blood sugar by controlling the metabolism of blood sugar; enhancing immunity and disease resistance of patients. The formula of the invention adopts natural traditional Chinese medicine materials with food and medicine homology and auxiliary nutrient substances, and has scientific compatibility, and the functions of reducing blood sugar and stabilizing blood sugar are simultaneously realized, thereby avoiding the side effect of western medicines on patients. The formula of the invention has good effects of reducing blood sugar and stabilizing blood sugar, is convenient to take and causes no adverse reaction to patients.
Description
Technical field
The present invention relates to field of health care products, specifically one can stabilizing blood sugar and hypoglycemic compositions and preparation technology thereof.
Background technology
Have the diabetes of " affluenza " " laudatory title ", one to the phychology allowing people entertain " optimistic ".In the modern life, goods and materials
Extreme enrichment, we have taken leave of the hungry age and had but caused health hazard because of satiating sweet.Meanwhile, fast pace
Life, erratic work and rest and dietary habit, provide favourable hotbed to growing of disease.Diabetes, sound and just not having
Cancer or acquired immune deficiency syndrome (AIDS) are gloomy like that frightened, but, it but increases with invisible geometry situation, and a little nibbles our strong
Health.
Survey result shows, Chinese adult diabetes prevalence is 11.6%, and the people being in prediabetes accounts for total population
50.1%.It is to say, less than in 10 adults, just have a diabetics;In each two adult, just there is one
Belong to prediabetes.Being carried out in the investigation of 2010 according to this, diabetes mellitus in China prevalence exceedes U.S.'s (11.3%);
Diabetics number reaches 1.14 hundred million, exceedes India and becomes diabetes the first big country worthy of the name.Carried out with 2007
A front national survey is compared, and between 3 years, the newly-increased diabetics of China just reaches 22,000,000 people, complete nearly equivalent to Australia
State's population.
Diabetes are one group of metabolic diseases being characterized with hyperglycemia.Hyperglycemia is then due to defect of insulin secretion or its biology
Act on impaired, or both have concurrently and cause.Long-standing hyperglycemia during diabetes, causes various tissue, particularly eye, kidney,
Heart, blood vessel, neural chronic lesion, dysfunction.Diabetics raises due to blood glucose, can cause peripheral angiopathy,
Cause local organization that the sensitivity of impairment factor is reduced and hypoperfusion, in extraneous factor damage local organization or local sense
During dye, relatively common people are easier to local tissue ulceration, and the modal position of this danger is exactly foot, therefore referred to as diabetic foot.
Due to hyperglycemia, hypertension and hyperlipidemia, Microcirculation of Renal Glomeruli filtration pressure is abnormal to be raised, and promotes Diabetic nephropathy to occur and development.
Early manifestation is albuminuria, edema, late period renal failure occurs, and is the topmost cause of death of type Ⅱdiabetes mellitus, and this is also
The harm of diabetes.Diabetic neuropathy is one of modal chronic complicating diseases of diabetes, is that diabetes are lethal and disable
Main cause.Diabetic neuropathy is most common with peripheral neuropathy and vegetative nerve lesion, and this is one of the harm of diabetes.
Diabetes are referred to as " quenching one's thirst " by the traditional Chinese medical science, as far back as B.C. 400 years, Huangdi's Internal Classics was just recorded " quenching one's thirst " this
One name of disease, " more than three " symptom is had been described in " Medical Treasures of the Golden Chamber quench one's thirst a piece " by Han dynasty well-known doctor's Zhang Zhongjing.
China's traditional medicine just has pointed out the five internal organs weakness, disorder of emotion, eating and drinking without temperance and diabetes in Huangdi's Internal Classics
There is close relationship.Hereafter ancient Chinese medicine doctor is continuously replenished performance on this basis, makes diabetes etiology and pathogenesis theoretical content
Day by day enrich, now diabetes etiology and pathogenesis is summarized as follows.
(1) cause of disease
1. the ferritic deficiency of YIN, the five internal organs are weak: the ferritic deficiency of YIN, and the five internal organs weakness is the intrinsic factor of diabetes morbidity, the virtual loss of lung spleen kidney
The morbidity of diabete plays a decisive role.
2. eating and drinking without temperance: long-term surfeit delicious food, pure wine savoury, cause transporting and transforming function of the spleen and stomach dereliction of duty, accumulate in accumulated heat, dryness-transformation consumes Tianjin, sends out and is
Quench one's thirst.Having been accepted as obesity at present is the important environmental factors that type 2 diabetes mellitus occurs.Due to taken long-term high caloric diet,
Physical exertion reduces, and causes fat, makes the sickness rate of diabetes also be gradually increased.This is completely the same with the understanding of traditional medicine
's.
3. disorder of emotion: long-term direct stimulation, causes mechanism of qi pent-up, and then fire-transformation, consumes lung stomach-Yin Tianjin and send out as quenching one's thirst.Essence
God's neural factors occurs in diabetes and has certain effect in development.Modern medicine think with the anxiety of spirit, emotion swash
Dynamic, psychological pressure etc., can cause the hormone secretion of the antagonism insulin such as growth hormone, epinephrine to increase, and make blood glucose liter
High.
4. labor is intended to excessively: the ferritic deficiency of YIN, and multiple because of sexual overstrain, labor is intended to excessively, the cloudy essence of loss, causes hyperactivity of fire caused by deficiency of YIN, upper steaming lung
Stomach and send out for quenching one's thirst.
(2) pathogenesis
In sum, it is known that the pathogenesis quenched one's thirst mainly has following:
1. pathological changes is in early days, cloudy body fluid deficiency consumption, scorching inclined Sheng.Chinese dynasties medical literature discuss diabetes pathogeny time mostly with
The scorching argument of the deficiency of YIN.In early days, basic pathogenesis is cloudy body fluid deficiency consumption to diabetes, scorching inclined Sheng, and the deficiency of YIN is this, scorching for mark.Scorching
More cloudy Tianjin is the most empty, the most empty scorching more Sheng in cloudy Tianjin, and the two influences each other, reciprocal causation.Though the diseased region of diabetes and the five internal organs
Relevant, but mainly dirty at lung, spleen (stomach), kidney three.
2. course of disease delay, impairment of both QI and YIN, venation block.If diabetes can not get the most appropriate treatment, then course of disease delay in early days,
Cloudy damage QI consumed, scorching yin-damaging and Qi consuming and cause deficiency of both QI and YIN, visceral dysfunction simultaneously, body fluid dysbolismus, QI-blood circulation is obstructed,
Life in phlegm-turbidity and blood stasis blood, whole body venation block, corresponding internal organs organ loses moistening of QI and blood and supports and many deteriorated cases occur.
3. the pathological changes later stage, deficiency of YIN affecting YANG, deficiency in both YIN and YANG, the mutual root of YIN YANG of the human, depends on each other for existence.Diabetes be originally the deficiency of YIN,
If with the passing of time the course of disease delays, deficiency of YIN affecting YANG, cause deficiency in both YIN and YANG eventually.
The method of western medical treatment diabetes is divided into oral drugs and injection for curing at present.Wherein oral drugs include sulfonylurea drugs,
Biguanides, α glucosidase inhibitor, euglycemic agent, meglitinide Insulin secretagogues;Injection class pancreas
Island element preparation has animal insulin, insulin human and insulin analog.According to being divided into effect fugitive, middle and long-acting pancreas action time
Island element, and has made mix preparation, such as Novolin 30R, excellent secretes woods 70/30.But the Therapeutic Method of above-mentioned doctor trained in Western medicine can only control
Blood glucose, and during oral drugs, Western medicine has many untoward reaction more and takes taboo, limitation is big, simultaneously need to long-term taking, right
The puzzlement in spirit and financial resources is caused in patient.And the maximum untoward reaction of insulin treatment is hypoglycemia, hypoglycemia will go out
Existing hypoglycemic symptom, controls difficulty big.
Summary of the invention
According to above-mentioned weak point, it is an object of the invention to provide one can stabilizing blood sugar and hypoglycemic compositions and preparation thereof
Technique.
For achieving the above object, technical program of the present invention lies in: one can stabilizing blood sugar and hypoglycemic compositions, by weight
Number meter includes following component: major ingredient is leaf of Cyclocarya paliurus Iljinskaja extract 8-12 part, Radix glehniae extract 10-15 part, Herba Hedyotidis Diffusae
Extract 8-12 part, Radix Glycyrrhizae extract 3-6 part, Flos lupuli (Flos Humuli Lupuli) extract 5-8 part, Thallus Laminariae (Thallus Eckloniae) dietary fiber powder 6-10 part, soybean peptide
Powder 6-10 part, Lac regis apis 5-8 part;Adjuvant is xylitol 3-5 part, erythritol 3-5 part, sodium carboxymethyl cellulose 3-6 part.
Preferably: described leaf of Cyclocarya paliurus Iljinskaja extract is that water extract and ethanol extract are in the mixture of 1:1 ratio.
The present invention also provide for a kind of can stabilizing blood sugar and the preparation technology of hypoglycemic compositions, it comprises the steps:
(1) weigh: weigh leaf of Cyclocarya paliurus Iljinskaja extract 8-12 part respectively, Radix glehniae extract 10-15 part, Herba Hedyotidis Diffusae carry
Take thing 8-12 part, Radix Glycyrrhizae extract 3-6 part, Flos lupuli (Flos Humuli Lupuli) extract 5-8 part, Thallus Laminariae (Thallus Eckloniae) dietary fiber powder 6-10 part, soy peptide powder
6-10 part, Lac regis apis 5-8 part;Adjuvant is xylitol 3-5 part, erythritol 3-5 part, sodium carboxymethyl cellulose 3-6 part, single
Solely deposit;
(2) pelletize: by leaf of Cyclocarya paliurus Iljinskaja extract, Radix glehniae extract, Herba Hedyotidis Diffusae extract, Radix Glycyrrhizae extract, medicated beer
In flower extract, Thallus Laminariae (Thallus Eckloniae) dietary fiber powder, soybean peptide immigration efficient wet granulator after mix homogeneously, add big Lac regis apis, then
Secondary mix homogeneously, makes granule;
(3) cladding: add xylitol, erythritol, sodium carboxymethyl cellulose, by wood after step (2) makes granule
Sugar alcohol, erythritol, sodium carboxymethyl cellulose are evenly coated at granule appearance;
(4) it is dried: wet granular is moved into Fast granulate machine dispersion and granulation, then moves in drying and granulating machine dry, until granule dries
Dry;
(5) granulate: dry granule is used Fast granulate machine granulate, is dispersed into uniform granule;
(6) tabletting: granule uses sheeting equipment carry out tabletting;
(7) packaging: using automatic packaging machine packaging, case after luggage box of going forward side by side again, warehouse-in preserves.
Leaf of Cyclocarya paliurus Iljinskaja, pungent;Micro-hardship;Property flat.Leaf of Cyclocarya paliurus Iljinskaja has invigorating the spleen for eliminating dampness, Clearing heat and removing obstruction of fu-organs, depressed liver-energy dispersing and QI regulating, enriching yin and nourishing kidney
Effect, to because dysfunction of the spleen, expectorant are turbid, addiction delicious food savoury, lazy dynamic, abdominal distention food stagnation, the liver silt stagnation of QI and the obesity that causes, have
Good improvement.Modern science experiment finds that leaf of Cyclocarya paliurus Iljinskaja contains the multiple important active ingredient such as polysaccharide, triterpene, saponin, flavone,
The most also detect aminoacid, vitamin, germanium, selenium, chromium, vanadium, zinc, ferrum, the trace element of the multiple preciousness such as calcium, can strengthen
Body immunity, antioxidation, defying age, suitable for modern three-hypers class chronic disease is drunk by people, effectively reduces triglyceride and gallbladder
Sterin, have mystery natural blood pressure lowering, blood sugar lowering, the function of blood fat reducing, simultaneously to strengthen body immunity, antioxidation,
Defying age, liver protecting therapy fatty liver have unique effect, especially to diabetic population, have notable hypoglycemic effect.
Radix Glehniae sweetness and bitterness is light, cool;Cold nature, sweet in the mouth, micro-hardship, enter lung, spleen channel.Radix Glehniae contain volatile oil, coumarin,
Starch, alkaloid, triterpenic acid, stigmasterol, each sterol, the compositions such as Radix Adenophorae (Radix Glehniae) is plain.It is demonstrated experimentally that Radix Glehniae can improve T cell
Ratio, improves lymhocyte transformation rate, leukocyte increasing, strengthens macrophage function, extends antibody and there is the time, improves B thin
Born of the same parents, promote immunologic function.Radix Glehniae can strengthen healthy energy, reduces disease, the generation of prophylaxis of cancer.There is nourishing YIN and clearing away lung-heat, stomach reinforcing
The effect promoted the production of body fluid, the dry cough expectorant curing mainly dry impairing the lung the moon is few, dry pharynx dryness in the nasal cavity, blood of coughing as long as the pulmonary tuberculosis deficiency of YIN, thermal burn stomach-Yin thirsty
Dry tongue, inappetence.
Herba Hedyotidis Diffusae, its patent medicine bitter in the mouth, light, cold in nature, primary efficacy is heat-clearing and toxic substances removing, medicinal powder for relieving pain knot, promoting urination to remove dampness, especially
Kind treatment all kinds inflammation.For tonsillitis, pharyngolaryngitis, urinary tract infection, pelvic inflammatory disease, appendicitis, hepatitis, bacillary dysentery,
Venom, tumor.Also can be used for alimentary tract cancer.Modern pharmacology research proves, the immunity of Hedyotidis Diffusae energy enhancing body
Power, the growth of suppression tumor cell, the pathogenic bacterium such as bacillus pyocyaneus, staphylococcus aureus, streptococcus pneumoniae, dysentery bacterium are had
Inhibitory action, is the good medicine of " heat-clearing and toxic substances removing " in fact.
Radix Glycyrrhizae is the root and rhizome of herbaceos perennial Radix Glycyrrhizae, and nature and flavor are sweet flat, GUIXIN, lung, spleen, stomach warp.Tool invigorating the spleen and replenishing QI,
Nourishing the lung to arrest cough, relieving spasm to stop pain, the merit of the mitigation property of medicine, its effective ingredient is glycyrrhizin, enoxolone, 4',7-Dihydroxyflavanone, Radix Glycyrrhizae
Polysaccharide is one of Chinese herbal medicine of commonly using clinically.Radix Glycyrrhizae also has antiinflammatory, anti-allergic effects, and the throat of inflammation and trachea can be protected to glue
Film.Radix Glycyrrhizae extractum and glycyrrhizic acid have the Detoxication of similar glucuronic acid to some poisonous substance.Subacid contained by Radix Glycyrrhizae can block cause
The effect of cancer thing induced tumor growth.
Flos lupuli (Flos Humuli Lupuli) is put down, bitter in the mouth.Containing Humulone (humulone), heteronomy oxadiazon A and B, oxadiazon (cohumulone),
.beta.-bitter acid (lupulone), poly-.beta.-bitter acid (adlupulone), myrcene (myrcene), humulene (humulene),
Linalool, Fols lupuli alcohol, globulariacitrin, tannin, choline.Invigorating the stomach and promoting digestion, preventing phlegm from forming and stopping coughing, anti-consumptive disease, diuresis of calming the nerves.For appetite
Depressed, abdominal distention, pulmonary tuberculosis, pleuritis, insomnia, hysteria, edema, cystitis.
Thallus Laminariae (Thallus Eckloniae) salty in the mouth, cold in nature;Enter liver, stomach, kidney, lung meridian.Dietary fiber be a kind of can not by the carbohydrate of human consumption,
It is divided into the water-insoluble and big class of water-soluble fibre two.Cellulose, hemicellulose and lignin are 3 kinds of common non-soluble fibers,
It is present in plant cell wall;And pectin and natural gum etc. belong to water-soluble fibre, then it is present in the non-fiber material of nature.
Seaweed gel mass-energy promotes internal radioactive substance to excrete in company with stool, reduces the occurrence probability of radiation disease.Thallus Laminariae (Thallus Eckloniae) contains
Having substantial amounts of dietary fiber, can increase the satiety of overweight people, and Thallus Laminariae (Thallus Eckloniae) fat content is the lowest, heat is little, is fat
The food of person's fat-reducing.Containing the emplastic in substantial amounts of Algin, i.e. Thallus Laminariae (Thallus Eckloniae) in Thallus Laminariae (Thallus Eckloniae).It is a kind of water soluble dietary fiber,
Can be combined with the cholesterol in food, discharge it external, there is blood sugar lowering, blood fat reducing, anti-hunger, fat-reducing, relieving constipation, gas defence
The effects such as removing toxic substances, increase resistance against diseases.Algin also has removing carcinogen and alpha-contamination effect.In dietary fiber
Pectin can extend food enteral the time of staying, reduce glucose infiltration rate, make will not steeply rise into post-prandial glycemia,
Be conducive to the improvement of diabetic condition.Showing through scholar's research, dietary fiber has the hypoglycemic effect of fall, the experiment proved that,
26 grams of edible corn brans (fibre-bearing 91.2%) or soybean peel (fibre-bearing 86.7%) is added every day in meals.Result is 28
After 30 days, carbohydrate tolerance has clear improvement.Therefore, diabetic diet medium-term and long-term increase dietary fiber, it is possible to decrease insulin requirement
Amount, controls the metabolism after having meal, be as a kind of ancillary method for the treatment of diabetes.
Soy peptide powder be a kind of be made up of 2-6 aminoacid, molecular weight is at the hybrid peptide product of 200-800Dalton.Soybean peptide
Powder has perfect nutritive value, quickly supplements the whole protein nutrition of needed by human body, improves immunity;Can quickly repair flesh
Meat damage, promotion wound healing;Regain one's strength, strengthen muscle strength, improve motor capacity;Reduce pathologic exception leukocyte
Increase, improve the mental status of old people, slow down aging;Regulation reduces blood fat, blood pressure, cholesterol;Antioxidation, beauty treatment;
Improve sleep;Sport people post exercise muscular soreness can be alleviated, strengthen exercise tolerance, improve motor capacity;To α in human body-
Glucosidase has slow inhibitory action, glucose in energy decomposer rapidly, when being used together with other carbohydrates and saccharide,
Do not affected by amount of insulin secretion, the effect that suppression blood glucose rises rapidly can be played;Soybean protein through special biological enzyme action
Many Toplink stimulate the secretion of internal thyroxin, promote the bile acidification of cholesterol, reduce the intestinal absorption to cholesterol, and
It is promoted to excrete with feces;Soybean protein polypeptide through special biological enzyme action can suppress Angiotensin-Converting (ACE)
Activity.ACE is a kind of carboxylic dipeptidase, and angiotensin I generates the liter blood pressure bioactive peptide that activity is the strongest under the effect of ACE
Angiotensin, the latter's vasoactive smooth muscle, causes vasoconstriction, makes increasing of blood pressure persistence.Suppress as ACE
The soybean peptide of agent, it is possible to reduce the formation of angiotensinⅡ, anti-hemostatic tube end-contraction, reach the purpose of blood pressure lowering.
Rich in proteins, aminoacid, vitamin, mineral, enzyme, nucleic acid and distinctive material----Royal Jelly acid in fresh royal jelly
Deng 100 various active material and nutritional labelings.Royal Jelly acid is one of important functional component of Lac regis apis, improves cell by regulation
And humoral immune function and be obviously improved body immunity, thus there is physical strength reinforcing, improve immunity, enhancing development,
Promote the effects such as damaged tissues rehabilitation.Research finds, Lac regis apis, containing the Insulin-Like peptides of beneficially diabetes patient, is regulation blood
The active substance of sugar, can promote the secretion of insulin, make the metabolism of blood glucose be normally carried out.Additionally, sterling fresh royal jelly rich in
VB6 can prevent the formation of human body Neihuang County carbamide, alleviate the destruction to insulin.Lac regis apis can promote liver in carbohydrate metabolism more
Good performance effect, particularly can promote the function of exogenous glucose synthesis hepatic glycogen, plays the hypoglycemic effect of fall.
Xylitol does the sweeting agent of diabetes patient, supplementary and auxiliary therapeutical agent: xylitol is the centre of human body carbohydate metabolism
Body, lacks in the case of insulin affects carbohydrate metabolism in vivo, promotes without insulin, and xylitol also can pass through cell membrane, by group
Knit and absorb, promote liver glycogen synthesis, for cell with nutrition and energy, and blood glucose value will not be caused to raise, eliminate diabetes
People take after symptom more than three (polyphagia, polydipsia, polyuria), be the trophism being best suitable for patients with diabetes mellitus sugar replace
Product.Xylitol can promote that liver glycogen synthesizes, and blood glucose will not rise, and has hepatopath and improves liver function and lipotropic effect,
Treat B-mode chronic persistent hepatitis, chronic hepatitis B and liver cirrhosis and have obvious curative effects, be the preferable adjuvant of hepatitis concurrent disease patient
Thing.Xylitol is the natural stabiliser of insulin, will not increase insulin in blood after food, and xylitol also plays stable
The key player of hormone.
Erythritol is not degraded by enzyme, can only pass through kidney (easily by intestinal absorption) and drain into discharge in urine from blood, be not involved in
Carbohydrate metabolism and change of blood sugar, therefore it is suitable for patients with diabetes mellitus.Colon will not ferment, gastrointestinal upset can be avoided.
Sodium carboxymethyl cellulose be glucose polymerization degree be the cellulose derivative of 100~2000, relative molecular mass 242.16.?
Medical industry can be made the emulsion stabilizer of injection, the binding agent of tablet and film former.
Li Dong Yuan is pointed out: " abundance of vigour, is all filled by QI of the spleen and stomach, then can nourish vigour ", highlights taste to unit
The effect of supplementing nutrition of gas.Whether " congenital essence " or " acquired essence ", it is required for taste and nutrition is provided continuously,
Could contain and not wane, being normally carried out of the activity that sustains life.Taste maintenance is the most important thing of health preserving as can be seen here.
With Herba Hedyotidis Diffusae, Radix Glehniae as monarch drug in this prescription, consuming from pathogeny the moon body fluid deficiency of diabetes, scorching partially getting out is sent out,
Heat-clearing and toxic substances removing, YIN nourishing and the production of body fluid promoting, fundamentally treat and nurse one's health the body constitution of diabetes patient;With leaf of Cyclocarya paliurus Iljinskaja as ministerial drug, assist monarch drug,
Clearing heat and removing obstruction of fu-organs, enriching yin and nourishing kidney further;Flos lupuli (Flos Humuli Lupuli) is adjuvant drug, on the one hand assists monarch, ministerial drug, strengthens therapeutical effect, the opposing party
Face, mainly some complication of the internal organs that treatment causes because of diabetes;Radix Glycyrrhizae, for making medicine, plays the effect relaxing each property of medicine,
Furthermore, Radix Glycyrrhizae invigorating the spleen and replenishing QI, relieving spasm to stop pain, alleviate pain when patient's disease is sent out, supplement my vigour simultaneously, help patient body
The rehabilitation of energy.Furthermore, the Algin in Thallus Laminariae (Thallus Eckloniae) belong to water soluble dietary fiber element, can extend food enteral the time of staying,
Reduce the infiltration rate of glucose, make will not steeply rise into post-prandial glycemia, the beneficially improvement of diabetic condition, play stable
The effect of blood glucose.3rd, Lac regis apis, containing the Insulin-Like peptides of beneficially diabetes patient, is the active substance of regulation blood glucose, energy
Promote the secretion of insulin, make the metabolism of blood glucose be normally carried out;Additionally, sterling fresh royal jelly rich in VB6 can prevent human body
The formation of Neihuang County's carbamide, alleviates the destruction to insulin.Lac regis apis can promote that liver preferably plays effect in carbohydrate metabolism, special
It not the function that can promote exogenous glucose synthesis hepatic glycogen, play the hypoglycemic effect of fall.Lac regis apis also has and is obviously improved
Body immunity, thus there is physical strength reinforcing, improve immunity, can strengthen for the resistance against diseases to diabetic complication.
Little molecule soy peptide powder easily absorbs, and has slow inhibitory action to alpha-glucosidase in human body, glucose in energy decomposer rapidly,
When being used together with other carbohydrates and saccharide, do not affected by amount of insulin secretion, suppression blood glucose can be played and rise rapidly
Effect;Can quickly supplement the whole protein nutrition of needed by human body simultaneously, improve immunity further.
This prescription collection heat clearing away YIN nourishing is main, is aided with regulation liver vigour, fundamentally reduces blood glucose, on the other hand by controlling blood
The metabolism of sugar carrys out stabilizing blood sugar;Strengthen the immunity of patient simultaneously, strengthen its resistance against diseases.Prescription of the present invention is by using sky
The Chinese medicine material of right Medicine Food Homology, is aided with nutrient substance, the compatibility of science, and blood sugar lowering and stabilizing blood sugar act on simultaneously, it is to avoid
The side effect that patient is produced by Western medicine.Prescription blood sugar lowering of the present invention and stabilizing blood sugar are respond well, taking convenience, patient without bad instead
Should.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention will be further described.
Embodiment 1
One stabilizing blood sugar and hypoglycemic compositions, by weight meter can include following component: major ingredient is that leaf of Cyclocarya paliurus Iljinskaja extracts
Thing 8 parts, Radix glehniae extract 10 parts, Herba Hedyotidis Diffusae extract 8 parts, Radix Glycyrrhizae extract 3 parts, Flos lupuli (Flos Humuli Lupuli) extract 5 parts,
6 parts of Thallus Laminariae (Thallus Eckloniae) dietary fiber powder, soy peptide powder 6 parts, Lac regis apis 5 parts;Adjuvant is xylitol 3 parts, erythritol 3 parts, carboxylic
Sodium carboxymethylcellulose pyce 3 parts.Wherein, leaf of Cyclocarya paliurus Iljinskaja extract is that water extract and ethanol extract are in the mixture of 1:1 ratio.
The present invention also provide for a kind of can stabilizing blood sugar and the preparation technology of hypoglycemic compositions, it comprises the steps:
(1) weigh: weigh respectively leaf of Cyclocarya paliurus Iljinskaja extract, Radix glehniae extract, Herba Hedyotidis Diffusae extract, Radix Glycyrrhizae extract,
Flos lupuli (Flos Humuli Lupuli) extract, Thallus Laminariae (Thallus Eckloniae) dietary fiber powder, soy peptide powder, Lac regis apis;Adjuvant is xylitol, erythritol, carboxymethyl fibre
Dimension element sodium, individually deposits;
(2) pelletize: by leaf of Cyclocarya paliurus Iljinskaja extract, Radix glehniae extract, Herba Hedyotidis Diffusae extract, Radix Glycyrrhizae extract, medicated beer
In flower extract, Thallus Laminariae (Thallus Eckloniae) dietary fiber powder, soybean peptide immigration efficient wet granulator after mix homogeneously, add big Lac regis apis, then
Secondary mix homogeneously, makes granule;
(3) cladding: add xylitol, erythritol, sodium carboxymethyl cellulose, by wood after step (2) makes granule
Sugar alcohol, erythritol, sodium carboxymethyl cellulose are evenly coated at granule appearance;
(4) it is dried: wet granular is moved into Fast granulate machine dispersion and granulation, then moves in drying and granulating machine dry, until granule dries
Dry;
(5) granulate: dry granule is used Fast granulate machine granulate, is dispersed into uniform granule;
(6) tabletting: granule uses sheeting equipment carry out tabletting;
(7) packaging: using automatic packaging machine packaging, case after luggage box of going forward side by side again, warehouse-in preserves.
Embodiment 2
One stabilizing blood sugar and hypoglycemic compositions, by weight meter can include following component: major ingredient is that leaf of Cyclocarya paliurus Iljinskaja extracts
Thing 12 parts, Radix glehniae extract 15 parts, Herba Hedyotidis Diffusae extract 12 parts, Radix Glycyrrhizae extract 6 parts, Flos lupuli (Flos Humuli Lupuli) extract 8
Part, 10 parts of Thallus Laminariae (Thallus Eckloniae) dietary fiber powder, soy peptide powder 10 parts, Lac regis apis 8 parts;Adjuvant is xylitol 5 parts, erythritol 5
Part, sodium carboxymethyl cellulose 6 parts.Wherein, leaf of Cyclocarya paliurus Iljinskaja extract is that water extract and ethanol extract are in the mixture of 1:1 ratio.
The present invention also provide for a kind of can stabilizing blood sugar and the preparation technology of hypoglycemic compositions, it comprises the steps:
(1) weigh: weigh respectively leaf of Cyclocarya paliurus Iljinskaja extract, Radix glehniae extract, Herba Hedyotidis Diffusae extract, Radix Glycyrrhizae extract,
Flos lupuli (Flos Humuli Lupuli) extract, Thallus Laminariae (Thallus Eckloniae) dietary fiber powder, soy peptide powder, Lac regis apis;Adjuvant is xylitol, erythritol, carboxymethyl fibre
Dimension element sodium, individually deposits;
(2) pelletize: by leaf of Cyclocarya paliurus Iljinskaja extract, Radix glehniae extract, Herba Hedyotidis Diffusae extract, Radix Glycyrrhizae extract, medicated beer
In flower extract, Thallus Laminariae (Thallus Eckloniae) dietary fiber powder, soybean peptide immigration efficient wet granulator after mix homogeneously, add big Lac regis apis, then
Secondary mix homogeneously, makes granule;
(3) cladding: add xylitol, erythritol, sodium carboxymethyl cellulose, by wood after step (2) makes granule
Sugar alcohol, erythritol, sodium carboxymethyl cellulose are evenly coated at granule appearance;
(4) it is dried: wet granular is moved into Fast granulate machine dispersion and granulation, then moves in drying and granulating machine dry, until granule dries
Dry;
(5) granulate: dry granule is used Fast granulate machine granulate, is dispersed into uniform granule;
(6) tabletting: granule uses sheeting equipment carry out tabletting;
(7) packaging: using automatic packaging machine packaging, case after luggage box of going forward side by side again, warehouse-in preserves.
Embodiment 3
One stabilizing blood sugar and hypoglycemic compositions, by weight meter can include following component: major ingredient is that leaf of Cyclocarya paliurus Iljinskaja extracts
Thing 10 parts, Radix glehniae extract 12 parts, Herba Hedyotidis Diffusae extract 10 parts, Radix Glycyrrhizae extract 5 parts, Flos lupuli (Flos Humuli Lupuli) extract 6
Part, 8 parts of Thallus Laminariae (Thallus Eckloniae) dietary fiber powder, soy peptide powder 8 parts, Lac regis apis 6 parts;Adjuvant be xylitol 4 parts, erythritol 4 parts,
Sodium carboxymethyl cellulose 5 parts.Wherein, leaf of Cyclocarya paliurus Iljinskaja extract is that water extract and ethanol extract are in the mixture of 1:1 ratio.
The present invention also provide for a kind of can stabilizing blood sugar and the preparation technology of hypoglycemic compositions, it comprises the steps:
(1) weigh: weigh respectively leaf of Cyclocarya paliurus Iljinskaja extract, Radix glehniae extract, Herba Hedyotidis Diffusae extract, Radix Glycyrrhizae extract,
Flos lupuli (Flos Humuli Lupuli) extract, Thallus Laminariae (Thallus Eckloniae) dietary fiber powder, soy peptide powder, Lac regis apis;Adjuvant is xylitol, erythritol, carboxymethyl fibre
Dimension element sodium, individually deposits;
(2) pelletize: by leaf of Cyclocarya paliurus Iljinskaja extract, Radix glehniae extract, Herba Hedyotidis Diffusae extract, Radix Glycyrrhizae extract, medicated beer
In flower extract, Thallus Laminariae (Thallus Eckloniae) dietary fiber powder, soybean peptide immigration efficient wet granulator after mix homogeneously, add big Lac regis apis, then
Secondary mix homogeneously, makes granule;
(3) cladding: add xylitol, erythritol, sodium carboxymethyl cellulose, by wood after step (2) makes granule
Sugar alcohol, erythritol, sodium carboxymethyl cellulose are evenly coated at granule appearance;
(4) it is dried: wet granular is moved into Fast granulate machine dispersion and granulation, then moves in drying and granulating machine dry, until granule dries
Dry;
(5) granulate: dry granule is used Fast granulate machine granulate, is dispersed into uniform granule;
(6) tabletting: granule uses sheeting equipment carry out tabletting;
(7) packaging: using automatic packaging machine packaging, case after luggage box of going forward side by side again, warehouse-in preserves.
Carrying out effect experimental with the compositions that prescription described in embodiment 3 and preparation method prepare, specific experiment is as follows.
1, zoopery
The preparation of experiment reagent: take the compositions that the prescription with embodiment 3 and preparation method prepare, dissolves after pulverizing, joins respectively
Make the solution of 80mg/ml, now with the current.
Animal packet and model are set up: with purebred Japan large ear rabbit as laboratory animal, empty stomach 48h (freely drinking water) before modeling,
By body weight auricular vein injection 110mg/kg alloxan (being configured to the aqueous solution of 5%, matching while using), propel in 30s
Bi Huifu feeding.After injection 3d, the rabbit ear edge vein exploitating blood of fasting 12h is surveyed blood glucose.To the family's rabbit ear edge after fasting 12h
Venous blood collection 0.5mL, EDTA anticoagulant.It is centrifuged immediately after, takes 10 μ L serum after being centrifuged, measure the blood glucose of all rabbit.
According to the principle of male and female half and half, select 48 blood glucose higher than 13mmol/L person for testing altogether.48 rabbit are randomly divided into 3
Group, often 2 repetitions of group, each repetition 8.If diabetic model group, diabetes pill positive controls, treatment group 3 process.
Separately take 8 rabbit before modeling and set blank group, male and female half and half, the rabbit ear edge same dosage of intravenous injection alloxan of being in during modeling
Normal saline.
Blood sugar lowering is tested: treatment group, diabetes pill group press 8g/ (kg d) gavage respectively;Diabetic model group and blank group sky respectively
Abdomen gavage equal-volume distilled water.Being carried out continuously 5 weeks, weighs and takes a blood sample and survey blood sugar concentration (fasting 12h) in the 7th day weekly.
Carbohydrate tolerance is tested: after testing 5 weeks continuously, gathers last fasting glucose as blood glucose value during 0h;Each group distinguishes gavage Portugal again
Grape sugar juice 20g/kg;To glucose 0.5,1, after 2h, to rabbit ear edge vein exploitating blood, measure Rabbits ' Blood Sugar concentration respectively.
Blood sugar detection: use glucose-peroxidase method to measure.Computing formula is blood glucose (mmol/L)=(Au/As) × 5.55,
Wherein, Au is the absorbance of sample;As is the absorbance of dextrose standard sample;5.55 be constant.
The impact of body weight: every time weigh the body weight of every rabbit, and record before gavage.
The present composition is shown in Table 1 to the experimental result of diabetic rabbit blood sugar influence.
The experimental result that diabetic rabbit body weight is affected by the present composition is shown in Table 2.
The experimental result that diabetic rabbit glucose tolerance is affected by the present composition is shown in Table 3.
The impact on diabetic rabbit blood glucose of table 1 present composition
Note: 1. A represents that difference is extremely notable (P < 0.01) compared with blank group;A represents significant difference compared with blank group
(P<0.05);B represents that difference is extremely notable (P < 0.01) compared with diabetic model group;B represents difference compared with diabetic model group
Significantly (P < 0.05).
From table 1, through experiment in 5 weeks, the blood sugar concentration of diabetes model matched group is constantly in higher level, and fluctuation
Scope is little, and other blood sugar concentrations respectively organized all have decline in various degree along with the carrying out of gavage.After to rabbit gavage 2 weeks,
The blood sugar concentration for the treatment of group rabbit has more apparent decline (P < 0.05);After gavage 3 weeks, diabetes pill group and the blood glucose for the treatment of group
Concentration has declined, and difference all reaches significant level (P < 0.05) compared with diabetic model group;After gavage 5 weeks, diabetes pill
The blood sugar concentration of group and treatment group declines the most again, and difference all reaches significant level (P < 0.05) compared with diabetic model group, and
The blood sugar concentration for the treatment of group relatively diabetes pill group blood sugar concentration declines substantially.
The impact on diabetic rabbit body weight of table 2 present composition
Note: 1. A represents that difference is extremely notable (P < 0.01) compared with blank group;A represents significant difference compared with blank group
(P<0.05);B represents that difference is extremely notable (P < 0.01) compared with diabetic model group;B represents difference compared with diabetic model group
Significantly (P < 0.05).
From table 2, through to the rabbit gavage of 5 weeks, the body weight of blank group rabbit is by (1.91 ± 0.26) before testing
Kg rises to (2.45 ± 0.31) kg, shows that existing experimental condition is suitable for rabbit growth.From beginning in the 1st week of test to off-test,
The body weight of diabetes model matched group is dropped to (1.32 ± 0.19) kg by (1.88 ± 0.14) kg, hence it is evident that less than blank group
Body weight (P < 0.01), this explanation artificial diabetes can cause rabbit weight loss.The treatment group of the gavage present composition and quenching one's thirst
The body weight of ball group also can decline, but t assay shows, it can slow down the decline of artificial diabetes rabbit body weight;Wherein control
Treatment group rabbit starts body weight on the 3rd week from gavage and gradually rises, and the rising of body weight is faster than diabetes pill group, after gavage the 5th week,
Significant difference (P < 0.05) compared with diabetes pill group.
The impact on diabetic rabbit glucose tolerance of table 3 present composition
Note: A represents that difference is extremely notable (P < 0.01) compared with blank group;A represents significant difference compared with blank group
(P<0.05)。
From table 3, after giving rabbit glucose 0.5h, the blood glucose value for the treatment of group and diabetes pill group is the most to some extent less than sugar
Urine disease model matched group;And after giving glucose 1h, the blood sugar concentration for the treatment of group rabbit is significantly lower than diabetes model matched group,
Illustrate that the present composition can strengthen the glucose tolerance of alloxan diabetes mice, and post-prandial glycemia can be suppressed quickly
Rising, and effect is more notable than diabetes pill group.
2, human experimentation
Type ii diabetes diagnostic criteria: with reference to the diabetes cause of disease credit of publication on the Diabetes Care magazine in July, 1997
Type standard, all diagnostic criterias meeting diabetes, insulin release test result meets the one of following condition and is i.e. diagnosed as 2 types
Diabetes.1. it is that main companion's relative insulin is not enough with insulin resistant.2. insulin substantially lacks companion's insulin resistant.The most true
1. the person of examining can not do, 2..
Chinese medical discrimination diagnostic criteria: deficiency of both QI and YIN or double heat syndrome: (1) primary symptom: fatigue and weakness, thirst and liking drink, the most hungry polyphagia, urine
Many.(2) secondary disease: dysphoria with feverish sensation in the chest palms and soles, spontaneous perspiration or night sweat, breathe hard lazy speech, cardiopalmus, constipation.(3) tongue arteries and veins: red tongue with a little fluid or corpulent tongue
Greatly, thready pulse or count accurately.Indispensable 1 of above primary symptom, adds time disease 2, the most diagnosable with reference to tongue arteries and veins.
Carry out clinical experiment with Qingdao hospital, observe patients with NIDDM 160 example altogether, use as described in Example 3 group
The compositions that side and preparation method prepare, two groups of patients, in aspect all similar such as sex, age, the course of disease and clinical manifestations, have
Comparability.Its clinical test results is as follows:
Test group 80 example: the present composition, three times a day, in terms of 0.65g, takes for every before the meal half an hour by each 3,
Take 4 weeks continuously.
Matched group 80 example: JIANGTANGNING JIAONANG, three times a day, takes before the meal, takes 4 weeks continuously half an hour by each 3.
Forbid during test merging and apply other blood sugar lowering Western medicine, merge Western medicine Uniform provisions as follows:
Moderate state of an illness experimenter: husky (glipizide) 2.5mg 3 times/day of enlightening, clothes half an hour before the meal.
Severe state of an illness experimenter: husky (glipizide) 5mg 2 times/day of enlightening (the most once), clothes half an hour before the meal.
Curative effect index: symptom, sign, fasting glucose, post-prandial glycemia, glycolated hemoglobin, glycated serum protein.
Secondary efficacy index: blood fat, lectin from hemolymph.
Safety indexes: routine blood test, routine urinalysis, just routine, electrocardiogram, liver function, renal function
Statistics: efficacy analysis employing meets scheme collection and is analyzed, safety analysis uses intentional analysis collection to be analyzed.Real
Test and the results are shown in Table 4-6.
Table 4 present composition and the contrast of conventional therapy diabetes fasting glucose curative effect situation
Table 5 present composition and the contrast of conventional therapy diabetes post-prandial glycemia curative effect situation
Table 6 present composition and the contrast of conventional therapy glycosuria tcm symptom curative effect situation
From table 4-6, test group is preferable for empty stomach and the Postprandial glucose control effect of diabetics, wherein, and fasting blood
The effective percentage that sugar controls is 97.5%, and the effective percentage of Postprandial glucose control is 96.25%, and the effective percentage that tcm symptom controls is 97.5%,
And it is superior to the scheme of conventional therapy.Furthermore, ratio evident in efficacy is above conventional therapy group.In process of the test, patient is not
See hepatic and renal function and the toxic and side effects of blood system and untoward reaction.
Claims (3)
1. one kind can stabilizing blood sugar and hypoglycemic compositions, it is characterised in that: meter by weight includes following component: major ingredient is green grass or young crops
Money Folium Salicis Babylonicae extract 8-12 part, Radix glehniae extract 10-15 part, Herba Hedyotidis Diffusae extract 8-12 part, Radix Glycyrrhizae extract 3-6
Part, Flos lupuli (Flos Humuli Lupuli) extract 5-8 part, Thallus Laminariae (Thallus Eckloniae) dietary fiber powder 6-10 part, soy peptide powder 6-10 part, Lac regis apis 5-8 part;Adjuvant
For xylitol 3-5 part, erythritol 3-5 part, sodium carboxymethyl cellulose 3-6 part.
The most according to claim 1 can stabilizing blood sugar and hypoglycemic compositions, it is characterised in that: described leaf of Cyclocarya paliurus Iljinskaja extracts
Thing is that water extract and ethanol extract are in the mixture of 1:1 ratio.
The most according to claim 1 can stabilizing blood sugar and the preparation technology of hypoglycemic compositions, it is characterised in that: it include as
Lower step:
(1) weigh: weigh leaf of Cyclocarya paliurus Iljinskaja extract 8-12 part, Radix glehniae extract 10-15 part, Herba Hedyotidis Diffusae extract respectively
8-12 part, Radix Glycyrrhizae extract 3-6 part, Flos lupuli (Flos Humuli Lupuli) extract 5-8 part, Thallus Laminariae (Thallus Eckloniae) dietary fiber powder 6-10 part, soy peptide powder 6-10
Part, Lac regis apis 5-8 part;Adjuvant is xylitol 3-5 part, erythritol 3-5 part, sodium carboxymethyl cellulose 3-6 part, individually deposits
Put;
(2) pelletize: leaf of Cyclocarya paliurus Iljinskaja extract, Radix glehniae extract, Herba Hedyotidis Diffusae extract, Radix Glycyrrhizae extract, Flos lupuli (Flos Humuli Lupuli) are carried
Take thing, Thallus Laminariae (Thallus Eckloniae) dietary fiber powder, soybean peptide move in efficient wet granulator after mix homogeneously, add big Lac regis apis, again mix
Close uniformly, make granule;
(3) cladding: after step (2) makes granule, add xylitol, erythritol, sodium carboxymethyl cellulose, by xylitol,
Erythritol, sodium carboxymethyl cellulose are evenly coated at granule appearance;
(4) it is dried: wet granular is moved into Fast granulate machine dispersion and granulation, then moves in drying and granulating machine dry, until granule is dried;
(5) granulate: dry granule is used Fast granulate machine granulate, is dispersed into uniform granule;
(6) tabletting: granule uses sheeting equipment carry out tabletting;
(7) packaging: using automatic packaging machine packaging, case after luggage box of going forward side by side again, warehouse-in preserves.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610267830.XA CN105708934A (en) | 2016-04-27 | 2016-04-27 | Composition capable of stabilizing blood sugar and reducing blood sugar and preparation process thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610267830.XA CN105708934A (en) | 2016-04-27 | 2016-04-27 | Composition capable of stabilizing blood sugar and reducing blood sugar and preparation process thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105708934A true CN105708934A (en) | 2016-06-29 |
Family
ID=56162377
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610267830.XA Withdrawn CN105708934A (en) | 2016-04-27 | 2016-04-27 | Composition capable of stabilizing blood sugar and reducing blood sugar and preparation process thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105708934A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107279419A (en) * | 2017-06-30 | 2017-10-24 | 湖北思慧生物科技有限公司 | It is a kind of that there is hypoglycemic, reducing blood lipid, strengthen immunity, pressed candy of anti-oxidation efficacy and its preparation method and application |
CN110897023A (en) * | 2019-11-13 | 2020-03-24 | 南京林业大学 | Wheat aleurone layer arabinoxylan hypoglycemic instant tea and preparation method thereof |
CN113288998A (en) * | 2020-02-21 | 2021-08-24 | 防城港济仁堂中医门诊部 | Chinese medicinal formula for stabilizing blood sugar diseases and preparation scheme |
-
2016
- 2016-04-27 CN CN201610267830.XA patent/CN105708934A/en not_active Withdrawn
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107279419A (en) * | 2017-06-30 | 2017-10-24 | 湖北思慧生物科技有限公司 | It is a kind of that there is hypoglycemic, reducing blood lipid, strengthen immunity, pressed candy of anti-oxidation efficacy and its preparation method and application |
CN110897023A (en) * | 2019-11-13 | 2020-03-24 | 南京林业大学 | Wheat aleurone layer arabinoxylan hypoglycemic instant tea and preparation method thereof |
CN113288998A (en) * | 2020-02-21 | 2021-08-24 | 防城港济仁堂中医门诊部 | Chinese medicinal formula for stabilizing blood sugar diseases and preparation scheme |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104856003A (en) | Non-full nutritional formula food for patients with diabetes | |
CN102526479B (en) | Health-care medicine formula with functions of enhancing immunity and lowering blood sugar | |
CN102526478B (en) | Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar | |
CN101156689B (en) | A functional food for diabetic | |
CN103446385A (en) | Traditional Chinese medicine preparation for treating diabetic complications | |
CN102205107A (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
CN103285145B (en) | Pure traditional Chinese medicine preparation for prompting rapid growth of pigs as well as preparation method and application method thereof | |
CN105708934A (en) | Composition capable of stabilizing blood sugar and reducing blood sugar and preparation process thereof | |
CN102578668B (en) | Beverage for assisting in reducing blood sugar | |
CN104857154A (en) | Traditional Chinese medicine composition for treating three-high diseases and preparation method therefor | |
CN105028995A (en) | Mixed dog food and preparation method thereof | |
CN102813870A (en) | Chinese herbal compound preparation used for treating alcoholism and gout and preparation method and application thereof | |
CN101085039A (en) | Composition for preventing and treating diabetes (hyperglycaemia) and its preparation method | |
CN102754833B (en) | Healthcare product with function of enhancing immunity and preparation method thereof | |
CN109771578A (en) | The composition for preventing and treating diabetes and complication | |
CN102872423A (en) | Traditional Chinese medicine compound for treating glycuresis and preparation method thereof | |
CN103055176B (en) | Traditional Chinese medicine for treating diabetes mellitus and preparation method thereof | |
CN113521134B (en) | Traditional Chinese medicine composition for treating type II diabetes and application | |
CN104644734A (en) | Drug for treating type II diabetes and complications thereof | |
CN103393938B (en) | Traditional Chinese medicine composition for reducing blood sugar | |
CN104042928B (en) | A kind of pharmaceutical composition for treating diabetes and its production and use | |
CN104587175B (en) | A kind of Chinese medicine preparation for treating diabetes | |
CN103340991B (en) | Oral liquid for nursing diabetics and preparation method thereof | |
CN102114206A (en) | Powder capable of restoring function of pancreatic islet and preparation method thereof | |
CN110680861A (en) | A Chinese medicinal composition for treating diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160629 |